Gupta, Neeraj http://orcid.org/0000-0002-5500-5218
Hanley, Michael J. http://orcid.org/0000-0001-9266-2797
Kerstein, David
Tugnait, Meera http://orcid.org/0000-0002-9005-375X
Narasimhan, Narayana
Marbury, Thomas C. http://orcid.org/0000-0002-6416-3314
Venkatakrishnan, Karthik http://orcid.org/0000-0003-4039-9813
Funding for this research was provided by:
Millennium Pharmaceuticals, Inc. (n/a)
Article History
Received: 1 February 2021
Accepted: 4 March 2021
First Online: 20 March 2021
Declarations
:
: NG: Employee of Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.MJH: Employee of Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.DK: Former employee and stock owner of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.MT: Former employee of ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.NN: Former employee of ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.TCM: Employee and equity owner of Orlando Clinical Research Center.KV: Former employee of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
: Approval for this study was obtained from the institutional review board of the study site (Orlando Clinical Research Center, Orlando, FL, USA).This study was conducted in accordance with current Good Clinical Practice, the Declaration of Helsinki, the International Council for Harmonisation guidelines, and all applicable regulatory requirements.
: All participants provided written informed consent.
: Not applicable.